4.5 Review

Let There Be Light: Gene and Cell Therapy for Blindness

Journal

HUMAN GENE THERAPY
Volume 27, Issue 2, Pages 134-147

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2015.147

Keywords

-

Funding

  1. Institut National de la Sante et de la Recherche Medicale (INSERM)
  2. Pierre et Marie Curie Universite (UPMC)
  3. Centre National de la Recherche Scientifique (CNRS)
  4. Foundation Fighting Blindness (FFB) [CD-CL-0808-0466-CHNO]
  5. French State program Investissements d'Avenir [LABEX LIFESENSES: ANR-10-LABX-65]

Ask authors/readers for more resources

Retinal degenerative diseases are a leading cause of irreversible blindness. Retinal cell death is the main cause of vision loss in genetic disorders such as retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis, as well as in complex age-related diseases such as age-related macular degeneration. For these blinding conditions, gene and cell therapy approaches offer therapeutic intervention at various disease stages. The present review outlines advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies. A significant body of preclinical evidence and initial clinical results pave the way for further development of these cutting edge treatments for patients with retinal degenerative disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available